These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 22550275

  • 1. Clinical outcomes associated with brand-to-generic phenytoin interchange.
    Kinikar SA, Delate T, Menaker-Wiener CM, Bentley WH.
    Ann Pharmacother; 2012 May; 46(5):650-8. PubMed ID: 22550275
    [Abstract] [Full Text] [Related]

  • 2. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ, Kamat S, Fang C.
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [Abstract] [Full Text] [Related]

  • 3. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS.
    Neurology; 2008 Aug 12; 71(7):525-30. PubMed ID: 18695164
    [Abstract] [Full Text] [Related]

  • 4. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
    Rascati KL, Richards KM, Johnsrud MT, Mann TA.
    Pharmacotherapy; 2009 Jul 12; 29(7):769-74. PubMed ID: 19558250
    [Abstract] [Full Text] [Related]

  • 5. Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations.
    Shin JW, Chu K, Jung KH, Lee ST, Moon J, Lee SK.
    Int J Clin Pharmacol Ther; 2014 Dec 12; 52(12):1017-22. PubMed ID: 25295717
    [Abstract] [Full Text] [Related]

  • 6. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, Harada AS, Curtis B.
    Epilepsia; 2011 Jul 12; 52(7):1365-71. PubMed ID: 21692778
    [Abstract] [Full Text] [Related]

  • 7. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs.
    Bautista RE, Gonzales W, Jain D.
    Epilepsy Res; 2011 Jun 12; 95(1-2):158-67. PubMed ID: 21530177
    [Abstract] [Full Text] [Related]

  • 8. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC.
    Neurology; 2004 Oct 26; 63(8):1494-6. PubMed ID: 15505173
    [Abstract] [Full Text] [Related]

  • 9. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
    Makus KG, McCormick J.
    Clin Ther; 2007 Feb 26; 29(2):334-41. PubMed ID: 17472825
    [Abstract] [Full Text] [Related]

  • 10. Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
    Vari MS, Pinto F, Mencaroni E, Giudizioso G, Minetti C, La Neve A, Francavilla T, Piccioli M, Striano S, del Gaudio L, Tovo P, Striano P, Verrotti A.
    Clin Drug Investig; 2016 Jan 26; 36(1):87-91. PubMed ID: 26507620
    [Abstract] [Full Text] [Related]

  • 11. Are generic drugs really inferior medicines?
    Moore N, Berdaï D, Bégaud B.
    Clin Pharmacol Ther; 2010 Sep 26; 88(3):302-4. PubMed ID: 20725079
    [Abstract] [Full Text] [Related]

  • 12. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.
    Expert Opin Pharmacother; 2009 Oct 26; 10(14):2317-28. PubMed ID: 19663636
    [Abstract] [Full Text] [Related]

  • 13. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS, Lan SK, Ou JH, Tzai TS.
    Clin Ther; 2007 Apr 26; 29(4):670-82. PubMed ID: 17617290
    [Abstract] [Full Text] [Related]

  • 14. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study.
    Polard E, Nowak E, Happe A, Biraben A, Oger E, GENEPI Study Group.
    Pharmacoepidemiol Drug Saf; 2015 Nov 26; 24(11):1161-9. PubMed ID: 26395769
    [Abstract] [Full Text] [Related]

  • 15. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F, Duh MS, Gosselin A, Paradis PE.
    Epilepsia; 2007 Mar 26; 48(3):464-9. PubMed ID: 17346246
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED.
    Aaronson PM, Belgado BS, Spillane JP, Kunisaki TA.
    Am J Emerg Med; 2011 Nov 26; 29(9):983-8. PubMed ID: 20685063
    [Abstract] [Full Text] [Related]

  • 17. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Perron R.
    Neurology; 2005 Apr 26; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15858865
    [No Abstract] [Full Text] [Related]

  • 18. Is bioavailability altered in generic versus brand anticonvulsants?
    Jankovic SM, Ignjatovic Ristic D.
    Expert Opin Drug Metab Toxicol; 2015 Mar 26; 11(3):329-32. PubMed ID: 25440299
    [Abstract] [Full Text] [Related]

  • 19. Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study.
    Suthisisang C, Payakachat N, Chulavatnatol S, Towanabut S.
    J Med Assoc Thai; 1998 Jan 26; 81(1):64-70. PubMed ID: 9470324
    [Abstract] [Full Text] [Related]

  • 20. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.
    Neurology; 2008 May 27; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.